Answers are grounded in this paper and cite their sources.
Among metabolites of vitamin D 3 , 25-hydroxycholecalciferol (25-(OH)D 3 ), also referred to as 25-hydroxyvitamin D 3 , is recognized for its bioavailability and utility in poultry rations. This four-arm randomized controlled trial evaluated the outcomes of three commercial products of 25-(OH)D 3 with varying active concentration on growth performance metrics, bone mineralization, and plasma 25-(OH)D 3 levels in broilers relative to an unsupplemented control. A total of 1,500 Ross broiler chicks were allocated to four treatments with 15 replicate pens of 25 birds in each replicate floor pen. Dietary treatments included: T1 - Basal diet (2000 IU/kg of finished feed) + 0 ppb supplemented 25-(OH)D 3 , T2 – Basal (2000 IU/kg) + Product A (69 ppb supplemented 25-(OH)D 3 ), T3 - Basal (2000 IU/kg) + Product B (69 ppb supplemented 25-(OH)D 3 ), and T4 – Basal (2000 IU/kg) + Product C (34.5 ppb supplemented 25-(OH)D 3 ). Performance parameters were recorded during starter (day 0 to 14), grower (day 14 to 28) and finisher (day 28 to 43) phases. Tibia mineral contents and plasma 25-(OH)D 3 were measured on day 21 and 43. Feed intake did not differ significantly during starter, grower, and finisher phase ( P > 0.05). Body weight gain was higher in Product A birds compared to Product B and Product C from 0 to 43 days ( P < 0.05). There were no differences between groups in tibia bone parameters on day 21. Tibia ash percentage on day 43 was significantly greater in Product A and Product C compared to the unsupplemented control ( P < 0.05). Tibia bone calcium, phosphorus, and density did not differ among treatment groups( P > 0.05). Plasma 25-(OH)D 3 was greater in product A compared to Product B and C at both 21 and 43 days( P < 0.05). All vitamin D 3 supplemented groups had greater plasma 25-(OH)D 3 compared to the unsupplemented control. Mortality rates were unaffected ( P > 0.05) by supplemental Vitamin D 3 . The improved performance of Product A is attributed to its higher active 25-(OH)D 3 concentration and formulation, underscoring that inclusion rate alone does not guarantee biological efficacy. These findings emphasize the importance of evaluating commercial 25-(OH)D 3 products as outcomes may vary depending on the delivery method and the practical context.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: